Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Single-cell analysis of senescent epithelia reveals targetable mechanisms promoting fibrosis
Eoin D. O’Sullivan, … , Hassan Dihazi, David A. Ferenbach
Eoin D. O’Sullivan, … , Hassan Dihazi, David A. Ferenbach
Published November 22, 2022
Citation Information: JCI Insight. 2022;7(22):e154124. https://doi.org/10.1172/jci.insight.154124.
View: Text | PDF
Research Article Cell biology Nephrology

Single-cell analysis of senescent epithelia reveals targetable mechanisms promoting fibrosis

  • Text
  • PDF
Abstract

Progressive fibrosis and maladaptive organ repair result in significant morbidity and millions of premature deaths annually. Senescent cells accumulate with aging and after injury and are implicated in organ fibrosis, but the mechanisms by which senescence influences repair are poorly understood. Using 2 murine models of injury and repair, we show that obstructive injury generated senescent epithelia, which persisted after resolution of the original injury, promoted ongoing fibrosis, and impeded adaptive repair. Depletion of senescent cells with ABT-263 reduced fibrosis in reversed ureteric obstruction and after renal ischemia/reperfusion injury. We validated these findings in humans, showing that senescence and fibrosis persisted after relieved renal obstruction. We next characterized senescent epithelia in murine renal injury using single-cell RNA-Seq. We extended our classification to human kidney and liver disease and identified conserved profibrotic proteins, which we validated in vitro and in human disease. We demonstrated that increased levels of protein disulfide isomerase family A member 3 (PDIA3) augmented TGF-β–mediated fibroblast activation. Inhibition of PDIA3 in vivo significantly reduced kidney fibrosis during ongoing renal injury and as such represented a new potential therapeutic pathway. Analysis of the signaling pathways of senescent epithelia connected senescence to organ fibrosis, permitting rational design of antifibrotic therapies.

Authors

Eoin D. O’Sullivan, Katie J. Mylonas, Rachel Bell, Cyril Carvalho, David P. Baird, Carolynn Cairns, Kevin M. Gallagher, Ross Campbell, Marie Docherty, Alexander Laird, Neil C. Henderson, Tamir Chandra, Kristina Kirschner, Bryan Conway, Gry H. Dihazi, Michael Zeisberg, Jeremy Hughes, Laura Denby, Hassan Dihazi, David A. Ferenbach

×

Figure 1

Senescent cell depletion during UUO results in increased renal fibrosis.

Options: View larger image (or click on image) Download as PowerPoint
Senescent cell depletion during UUO results in increased renal fibrosis....
(A) Schematic of murine senescent cell depletion during UUO experiment, with samples taken at days 0 and 7. Note senolytic ABT-263 administration daily from time of injury. n = 6–8 per group. (B) qPCR analysis of renal tissue after UUO showing reduction in markers of senescence cyclin dependent kinase inhibitor 1A (Cdkn1a), no change in myofibroblast markers Acta2, Ptprc, Pdgfrb, or Col3a1. * denotes P < 0.05 by ANOVA and Tukey test. RQ, relative quantification (fold change). (C) Representative images and quantification of immunofluorescence and of Picrosirius red staining of kidneys. Quantification of total staining per renal cortex. * denotes P < 0.05. PDGFRB: uninjured and vehicle-treated 5.69% (s.d. 2.23), uninjured and ABT-263–treated 7.53% (s.d. 2.48). UUO and vehicle-treated 33% (s.d. 5.67) versus UUO and ABT-263–treated 34.3% (s.d. 3.77). ANOVA, P = 0.921 95% CI: –4.2–6.75. α–Smooth muscle actin (α-SMA): uninjured and vehicle-treated 0.72% (s.d. 0.16), uninjured and ABT-263–treated 1.56% (s.d. 0.39). UUO and vehicle-treated 1.31% (s.d. 0.335) versus UUO and ABT-263–treated 19.9% (s.d. 6.96). ANOVA, P < 0.000 95% CI: 12.33–24.8. Collagen 1: uninjured and vehicle-treated 3.75% (s.d. 1.73), uninjured and ABT-263–treated 1.95% (s.d. 0.74). UUO and vehicle-treated 8.85% (s.d. 7.08) versus UUO and ABT-263–treated 14.5% (s.d. 6.58). ANOVA, P = 0.921 95% CI: -4.2–6.75. Picrosirius red: uninjured and vehicle-treated 2.1% (s.d. 0.26), uninjured and ABT-263–treated 2.33% (s.d. 0.34). UUO and vehicle-treated 6.5% (s.d. 0.81) versus UUO and ABT-263–treated 15.6% (s.d. 3.08). ANOVA, P < 0.000 95% CI: 6.8–11.3. For box plots, the center line represents the mean, the box limits the first and third quartiles, the whiskers ± 1.5 × IQR, and the points all the data. Scale bar = 100 μm.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts